Precigen, Inc.
PAPZIMEOS
Recurrent Respiratory Papillomatosis (RRP)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews PAPZIMEOS for Recurrent Respiratory Papillomatosis (RRP) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP validated by the European Medicines Agency and is under review.”